Health TrialsbyHealthPanel

Cardiology Research Dubrava Prospective Registry

ConditionsHeart FailureArrhythmias, CardiacAtrial FibrillationAcute Coronary Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Dubrava

About this trial

Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

patients with different cardiology pathology and diseases including arrhythmias, heart failure, venousn thromboembolism, implanted with CIED

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • SGLT-2 inh therapy, CIED implantation, thromboaspiration,

    Other intervention

    long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Treatment groups

3,000 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: Acute coronary syndrome - ACS1 intervention
Group B: Transcatheter aortic valve implantation - TAVI1 intervention
Group C: Venous thromboembolism - VTE1 intervention
Group D: Heart failure with SGLT2 inhibitor therapy included - HF-SGLT21 intervention
Group E: Cardiac implantable electronic device - CIED1 intervention
Group F: Arrhythmias0 interventions

Trial outcomes

Primary outcomes

1

cardiovascular death

death due to cardiovascular etiology during long term follow-up

Time frame
10 years
2

freedom from atrial arrhythmias

Freedom from atrial arrhythmias after PVI during mid-term folow-up (1 year) and long-term follow-up

Time frame
10 years
3

Time to revascularization

Time to revascularization during acute coronary syndrome

Time frame
10 years
4

Bleeding complications

Bleeding complications during long-term follow-up in patients prescribed with oral anticoagulation and/or antithrombotic therapy

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital Dubrava

Lead sponsor

Source ClinicalTrials.gov
Apply now